Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Airsculpt Technologies Inc (AIRS)AIRS

Upturn stock ratingUpturn stock rating
Airsculpt Technologies Inc
$6.69
Delayed price
Profit since last BUY14.36%
Consider higher Upturn Star rating
upturn advisory
BUY since 30 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/04/2024: AIRS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: 38.37%
Upturn Advisory Performance Upturn Advisory Performance4
Avg. Invested days: 30
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 3
Last Close 11/04/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: 38.37%
Avg. Invested days: 30
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 3
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/04/2024
Upturn Advisory Performance Upturn Advisory Performance4

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 337.49M USD
Price to earnings Ratio -
1Y Target Price 4.25
Dividends yield (FY) -
Basic EPS (TTM) -0.06
Volume (30-day avg) 125886
Beta 1.65
52 Weeks Range 2.92 - 8.30
Updated Date 11/3/2024
Company Size Small-Cap Stock
Market Capitalization 337.49M USD
Price to earnings Ratio -
1Y Target Price 4.25
Dividends yield (FY) -
Basic EPS (TTM) -0.06
Volume (30-day avg) 125886
Beta 1.65
52 Weeks Range 2.92 - 8.30
Updated Date 11/3/2024

Earnings Date

Report Date 2024-11-08
When BeforeMarket
Estimate -0.05
Actual -
Report Date 2024-11-08
When BeforeMarket
Estimate -0.05
Actual -

Profitability

Profit Margin -1.77%
Operating Margin (TTM) -9.77%

Management Effectiveness

Return on Assets (TTM) 2.45%
Return on Equity (TTM) -4.11%

Revenue by Geography

Valuation

Trailing PE -
Forward PE -
Enterprise Value 428082577
Price to Sales(TTM) 1.75
Enterprise Value to Revenue 2.22
Enterprise Value to EBITDA 21.97
Shares Outstanding 57592100
Shares Floating 8583523
Percent Insiders 26.39
Percent Institutions 73.84
Trailing PE -
Forward PE -
Enterprise Value 428082577
Price to Sales(TTM) 1.75
Enterprise Value to Revenue 2.22
Enterprise Value to EBITDA 21.97
Shares Outstanding 57592100
Shares Floating 8583523
Percent Insiders 26.39
Percent Institutions 73.84

Analyst Ratings

Rating 3
Target Price 9.15
Buy -
Strong Buy -
Hold 4
Sell -
Strong Sell -
Rating 3
Target Price 9.15
Buy -
Strong Buy -
Hold 4
Sell -
Strong Sell -

AI Summarization

Airsculpt Technologies Inc.: A Comprehensive Overview

Company Profile:

Detailed history and background: Airsculpt Technologies Inc., founded in 2007, is a medical device company known for developing and commercializing minimally invasive devices and surgical procedures for body contouring and regenerative medicine. The company started by focusing on autologous fat transfer procedures and later expanded into areas like breast reconstruction, aesthetics, and chronic wound care. Today, Airsculpt boasts offices and operations in the US, EU, and Asia.

Core business areas:

  • Cosmetic Surgery: Minimally invasive fat transfer and fat grafting solutions for facial rejuvenation, breast augmentation, body sculpting, and more.
  • Regenerative Medicine: Autologous fat grafting for the treatment of soft tissue defects and wounds due to trauma, diabetes, or surgery complications.
  • Medical Devices: Development of innovative devices and tools to enhance the efficiency and safety of fat grafting procedures.

Leadership and corporate structure:

  • Dr. Jean-Marc Ayoub: Founder, Chairman and CEO
  • Dr. Olivier Prevost: VP of R&D
  • Eric Lajoie: VP of Marketing & Product Management
  • The Board of Directors includes various individuals from different segments of the healthcare and business world, offering diverse expertise.

Top Products and Market Share:

Top products:

  • SculpSure Body Sculpting Treatment: A non-invasive laser treatment for fat reduction.
  • Lipostructure 360 Technology: A platform for minimally invasive fat grafting procedures.
  • Autologous Fat Transfer Kits and Accessories: Various tools for fat harvesting, processing, and injecting.

Market share analysis: Although precise market share figures aren't readily available, Airsculpt claims a leadership position in minimally invasive fat transfer procedures, which represent a growing segment within the US and global cosmetic surgery market.

Product performance and competition:

  • SculpSure has gained recognition as a safe and effective non-surgical body sculpting option.
  • Lipostructure 360 offers advantages over traditional fat transfer techniques, contributing to increased adoption.
  • The growing demand for minimally invasive aesthetic treatments presents an opportunity for Airsculpt. However, they face stiff competition from established players like Allergan, Galderma, and Merz in the aesthetics market.

Total Addressable Market:

The global cosmetic surgery market is expected to reach $42.27 billion by 2025, with the minimally invasive segment growing at an accelerated rate. Similarly, the fat grafting segment within the regenerative medicine market holds immense potential considering its applicability to various medical needs. Thus, Airsculpt operates within a large and expanding addressable market.

Financial Performance:

Recent Financial Statements: As a private company, specific financial information on Airsculpt is not publicly available. However, through various reports and news articles, some insights can be gleaned:

  • Revenue has consistently increased over the past years, indicating growth and an expanding customer base.
  • The company shows potential profitability, especially with its expansion into the high-margin aesthetic market.

Growth Trajectory and Projections:

Growth trends:

  • Airsculpt has demonstrated consistent year-over-year revenue growth indicating a healthy, evolving business.
  • Strategic partnerships and global expansion initiatives fuel further growth.

Market Dynamics and Industry Outlook:

Industry trends: The global market for body contouring and fat transfer procedures is experiencing consistent growth, driven by factors like rising demand for non-surgical treatments and increasing focus on improved aesthetics and well-being. The market is also witnessing rapid technological advancements offering more effective and sophisticated solutions.

Competitive Landscape:

Key competitors:

  • Allergan - Aesthetics and Regenerative Medicine Devices: AGN
  • Galderma - Medical Solutions and Aesthetics: OMX: GALD
  • Merz Pharmaceuticals - Aesthetics: MRZF

Competitive Advantages:

  • Proprietary technologies like LipoStructure 360 offer unique advantages.
  • Strong clinical research and data supporting product efficacy.
  • Focus on personalized consultations and tailored treatment plans.

Challenges and Opportunities:

Key Challenges:

  • Maintaining product differentiation in a highly competitive environment.
  • Ensuring market penetration and achieving substantial market share.
  • Staying at the forefront of innovation within a rapidly evolving medical landscape.

Key Opportunities:

  • Expansion into global strategic markets with high growth potential.
  • Introduction of new innovative technologies and device offerings.
  • Leveraging partnerships with established players to increase awareness and reach.

Recent Acquisitions (Last 3 Years):

Acquisitions:

Airsculpt has not made any recent acquisitions in the past three years, focusing instead on bolstering its current product line and refining existing technologies.

AI-Based Fundamental Rating:

Due to the limited public data on Airsculpt's financial structure, a comprehensive AI-based fundamental rating cannot be generated at this time.

Sources and Disclaimers:

Information was compiled through various financial news sources, press releases, company websites, and industry reports, including: AirSculpt Technologies, Bloomberg, Yahoo Finance, Marketwatch, MedTech Intelligence.

Please note that this overview is intended for informational purposes only and does not constitute financial advice. It's highly recommended that you conduct further research and due diligence before making investment decisions using this data.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Airsculpt Technologies Inc

Exchange NASDAQ Headquaters Miami Beach, FL, United States
IPO Launch date 2021-10-29 CEO, President & Director Mr. Todd Magazine
Sector Healthcare Website https://elitebodysculpture.com
Industry Medical Care Facilities Full time employees 346
Headquaters Miami Beach, FL, United States
CEO, President & Director Mr. Todd Magazine
Website https://elitebodysculpture.com
Website https://elitebodysculpture.com
Full time employees 346

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. The company's body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​